Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Pain Management Treatment Market to Catapult by 2018


Pain Management Treatment Market to Catapult by 2018

NEW YORK, NY -- (Marketwire) -- 03/11/13 -- TriMarkPublications.com cites in its newly published "Pain Management Treatment Markets" report that the pain management treatment market will catapult by 2018. For more information, visit: http://www.trimarkpublications.com/pain-management-treatment-markets/.

Pain management drugs, or analgesics, can be categorized into three main modalities: acetaminophen, NSAIDs and opioids. Pain, meanwhile, can be categorized into four main modalities: acute, chronic, neuropathic and nociceptive. The pain management market is currently valued at $52 billion. Growing at a rate of 20%, the opioid segment will constitute a full 43% of the pain management market by 2018. Although the U.S. market will only increase modestly to $21.8 billion, it remains the largest market by far throughout the forecast period.

The "Pain Management Treatment Markets" report covers:


 
--  CGRP antagonists
--  CB2 agonists
--  Sodium channel modulators
--  Calcium channel modulators
--  NMDA antagonists
--  P2x receptors
--  Trp channels
--  TrpV1 blockers
--  FAAH inhibitors
--  Novel opioids
--  Extended release formulations
--  Transdermal formulations

The "Pain Management Treatment Markets" report examines companies manufacturing pain management equipment and supplies in the world. Companies covered include: Abbott, AcelRx, Acura, Afferent, Algiax, Arcion, Astellas, BioDelivery Sciences, Cara, Cephalon, Convergence, Cytogel, DURECT, Egalet, Eli Lilly, Endo, Gruenenthal, Hospira, iMed, Johnson & Johnson, KemPharm, Mallinckrodt, NeurAxon, NeurogesX, Newron, Novartis, Nuvo, Pacira, Pain Therapeutics, Pfizer, Purdue, QRx, Relevare, Relmada, Spinifex, Xenon, Xenoport, Zalicus and Zogenix.

Detailed charts with sales forecasts and marketshare data are included. For more information, visit: http://www.trimarkpublications.com/pain-management-treatment-markets/.

About TriMarkPublications.com

TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit http://www.trimarkpublications.com.

Important Notice

The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.

Contact

TriMarkPublications.com Media Relations 1-888-OK-TRIMARK www.trimarkpublications.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement